Goldman Sachs
STLN

Goldman Sachs’s Starling Oncology STLN Stock Holding History

Goldman Sachs’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.42M Buy
1,735,337
+383,438
+28% +$1.61M ﹤0.01% 3294
2026
Q1 		$4.15M Buy
1,351,899
+781,475
+137% +$2.4M ﹤0.01% 3891
2025
Q4 		$2.03M Sell
570,424
-111,219
-16% -$412K ﹤0.01% 4574
2025
Q3 		$2.38M Buy
681,643
+527,011
+341% +$1.81M ﹤0.01% 4331
2025
Q2 		$317K Buy
154,632
+39,492
+34% +$98.7K ﹤0.01% 5411
2025
Q1 		$131K Buy
+115,140
New +$89.1K ﹤0.01% 5732
2022
Q2 		– Sell
-10,033
Closed -$72K – 6721
2022
Q1 		$72K Sell
10,033
-106,065
-91% -$716K ﹤0.01% 6193
2021
Q4 		$1.13M Buy
116,098
+99,326
+592% +$883K ﹤0.01% 4737
2021
Q3 		$167K Hold
16,772
– – ﹤0.01% 5782
2021
Q2 		$167K Buy
+16,772
New +$169K ﹤0.01% 5806
2021
Q1 		– Sell
-75,000
Closed -$810K – 6354
2020
Q4 		$810K Buy
+75,000
New +$772K ﹤0.01% 4330

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return

Goldman Sachs's STLN Position: Q2 2026 in Review

Goldman Sachs increased its Starling Oncology (STLN) stake by 28% in Q2 2026, buying an estimated $1.61M and bringing the position to 1,735,337 shares worth $9.42M. The position accounts for ﹤0.01% of the portfolio, ranked #3294.

Goldman Sachs first reported a position in STLN in Q4 2020 and has held it in 11 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Goldman Sachs held 1,735,337 shares of Starling Oncology worth $9.42M as of Q2 2026.
  • Goldman Sachs bought 383,438 Starling Oncology shares in Q2 2026, an estimated $1.61M.
  • Starling Oncology made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3294 holding.
  • Goldman Sachs first reported a position in Starling Oncology in Q4 2020 and has held it in 11 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.